Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-19-012560
Filing Date
2019-05-07
Accepted
2019-05-07 19:00:56
Documents
1
Period of Report
2019-05-07

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4629
  Complete submission text file 0000899243-19-012560.txt   6762
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Issuer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022
Business Address 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022 (212) 758-7325
Aperture Venture Partners IV, L.P. (Reporting) CIK: 0001659119 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38886 | Film No.: 19804675

Mailing Address 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022
Business Address 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022 212-758-7325
Aperture Ventures IV Management, LLC (Reporting) CIK: 0001775271 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38886 | Film No.: 19804676